Allo-HSCT for Core Binding Factor AML (t(8;21) or inv(16)/t(16;16)) in Second Complete Remission: Report from the Acute Leukemia Working Party of the EBMT

被引：0

作者：

Halaburda, Kazimierz ^{[1
]}

Labopin, Myriam ^{[2
]}

Mailhol, Audrey ^{[2
]}

Socie, Gerard ^{[3
]}

Craddock, Charles ^{[4
]}

Aljurf, Mahmoud ^{[5
]}

Beelen, Dietrich ^{[6
]}

Cornelissen, Jan ^{[7
]}

Bouhris, Jean-Henri ^{[8
]}

Labussiere-Wallet, Helene ^{[9
]}

Blaise, Didier ^{[10
]}

Gedde-Dahl, Tobias ^{[11
]}

Gilleece, Maria ^{[12
]}

Yakoub-Agha, Ibrahim ^{[13
]}

Mufti, Ghulam ^{[14
]}

Esteve, Jordi ^{[15
]}

Nagler, Arnon ^{[16
]}

机构：

[1] Inst Haematol & Transfus Med, Stem Cell Transplantat, Warsaw, Poland

[2] Univ Paris 06, Hop St Antoine, ALWP EBMT, Paris, France

[3] Hop St Louis, Paris, France

[4] Queen Elizabeth Hosp Birmingham, Birmingham, W Midlands, England

[5] King Faisal Specialist Hosp & Res Ctr, Riyadh, Saudi Arabia

[6] Univ Essen Gesamthsch, Essen, Germany

[7] Univ Med Ctr, Erasmus MC, Inst Canc, Rotterdam, Netherlands

[8] Gustave Roussy Canc Ctr, Villejuif, France

[9] Ctr Hosp Lyon Sud, Lyon, France

[10] Inst Paoli Calmettes, Marseille, France

[11] Oslo Univ Hosp, Oslo, Norway

[12] Leeds Teaching Hosp, Leeds, W Yorkshire, England

[13] Univ Lille, Hosp CHU Lille, LIRIC, INSERM,U995, Lille, France

[14] GKT Sch Med, London, England

[15] Hosp Clin Barcelona, Inst Hematol & Oncol, Barcelona, Spain

[16] Chaim Sheba Med Ctr, ALWP EBMT, Tel Hashomer, Israel

来源：

BONE MARROW TRANSPLANTATION | 2018年 / 53卷

关键词：

D O I：

暂无

中图分类号：

Q6 [生物物理学];

学科分类号：

071011 ;

摘要：

O021

引用

页码：28 / 29

页数：2

共 50 条

[1] Prognostic implication of additional cytogenetic aberrations in de novo acute myeloid leukemia (AML) with t(15;17), t(8;21) or inv(16)/t(16;16).
Wiernik, PH
Kim, H
Gundacker, H
Dewald, G
Slovak, ML
Paietta, E
Appelbaum, FR
Tallman, MS
BLOOD, 2001, 98 (11) : 457A - 457A
[2] Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Han, Se Young
Mrozek, Krzysztof
Voutsinas, Jenna
Wu, Qian
Morgan, Elizabeth A.
Vestergaard, Hanne
Ohgami, Robert
Kluin, Philip M.
Kristensen, Thomas Kielsgaard
Pullarkat, Sheeja
Moller, Michael Boe
Schiefer, Ana-Iris
Baughn, Linda B.
Kim, Young
Czuchlewski, David
Hilberink, Jacobien R.
Horny, Hans-Peter
George, Tracy, I
Dolan, Michelle
Ku, Nam K.
Yi, Cecilia Arana
Pullarkat, Vinod
Kohlschmidt, Jessica
Salhotra, Amandeep
Soma, Lori
Bloomfield, Clara D.
Chen, Dong
Sperr, Wolfgang R.
Marcucci, Guido
Cho, Christina
Akin, Cem
Gotlib, Jason
Broesby-Olsen, Sigurd
Larson, Melissa
Linden, Michael A.
Deeg, H. Joachim
Hoermann, Gregor
Perales, Miguel-Angel
Hornick, Jason L.
Litzow, Mark R.
Nakamura, Ryotaro
Weisdorf, Daniel
Borthakur, Gautam
Huls, Gerwin
Valent, Peter
Ustun, Celalettin
Yeung, Cecilia C. S.
BLOOD ADVANCES, 2021, 5 (10) : 2481 - 2489
[3] Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
Delaunay, J
Vey, N
Leblanc, T
Fenaux, P
Rigal-Huguet, F
Witz, F
Lamy, T
Auvrignon, A
Blaise, D
Pigneux, A
Mugneret, F
Bastard, C
Dastugue, N
Van den Akker, J
Fière, D
Reiffers, J
Castaigne, S
Leverger, G
Harousseau, JL
Dombret, H
BLOOD, 2003, 102 (02) : 462 - 469
[4] Genomic Landscape of Acute Myeloid Leukemia With t(8;21) and inv(16)
Motyko, Ekaterina
Kirienko, Anna
Kustova, Dariya
Prygunova, Mariya
Uspenskaya, Olga
Karyagina, Elena
Shuvaev, Vasilii
Voloshin, Sergey
Sidorkevich, Sergey
Martynkevich, Irina
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S295 - S296
[5] Encouraging Outcome of AML with t(8;16) Following Allogeneic Stem Cell Transplantation in First Remission - a Retrospective Analysis on Behalf of the Acute Leukemia Working Party of the EBMT
Schmaelter, Ann-Kristin
Labopin, Myriam
Versluis, Jurjen
Hernanz, Maria Pilar Gallego
Eder, Matthias
Borne, Peter A. Von Dem
Socie, Gerard
Chevallier, Patrice
Forcade, Edouard
Neubauer, Andreas
Baron, Frederic
Bazarbachi, Ali
Bug, Gesine
Nagler, Arnon
Schmid, Christoph
Esteve, Jordi
Ciceri, Fabio
Mohty, Mohamad
BLOOD, 2023, 142
[6] THERAPY-RELATED ACUTE MYELOID-LEUKEMIA WITH T(8, 21), INV(16), AND T(8, 16) - A REPORT ON 25 CASES AND REVIEW OF THE LITERATURE
QUESNEL, B
KATARJIAN, H
BJERGAARD, JP
BRAULT, P
ESTEY, E
LAI, JL
TILLY, H
STOPPA, AM
ARCHIMBAUD, E
HAROUSSEAU, JL
BAUTERS, F
FENAUX, P
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) : 2370 - 2379
[7] THERAPY-RELATED ACUTE MYELOID-LEUKEMIA (TAML) WITH T(8, 21), INV(16) OR T(8, 16) - A REPORT ON 25 CASES AND REVIEW OF THE LITERATURE
QUESNEL, B
KANTARJIAN, H
BJERGAARD, JP
BRAULT, P
LAI, JL
ESTEY, E
TILLY, H
STOPPA, AM
ARCHIMBAUD, E
HAROUSSEAU, JL
BAUTERS, F
FENAUX, P
BLOOD, 1993, 82 (10) : A126 - A126
[8] Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes
Kuwatsuka, Yachiyo
Miyamura, Koichi
Suzuki, Ritsuro
Kasai, Masaharu
Maruta, Atsuo
Ogawa, Hiroyasu
Tanosaki, Ryuji
Takahashi, Satoshi
Koda, Kyuhei
Yago, Kazuhiro
Atsuta, Yoshiko
Yoshida, Takashi
Sakamaki, Hisashi
Kodera, Yoshihisa
BLOOD, 2009, 113 (09) : 2096 - 2103
[9] COMPARISON OF EOSINOPHILS IN ACUTE NONLYMPHOCYTIC LEUKEMIA ASSOCIATED WITH THE T(8-21) AND INV(16)
BITTER, MA
LEBEAU, MM
BRITISH JOURNAL OF HAEMATOLOGY, 1985, 59 (01) : 185 - 188
[10] Excellent results of unpurged autotransplantation in first-remission acute myeloid leukemia with t(8;21), inv(16), and t(15;17).
Mehta, J
Powles, R
Sirohi, B
Treleaven, J
Kulkarni, S
Singhal, S
BLOOD, 2002, 100 (11) : 860A - 860A

← 1 2 3 4 5 →